Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain
Background Intraventricular hemorrhage (IVH) frequently complicates spontaneous intracerebral or subarachnoid hemorrhage (SAH). Administration of intraventricular tissue plasminogen activator (TPA) accelerates blood clearance, but optimal dosing has not been clarified. Using a standardized TPA dose, we assessed peak cerebrospinal fluid (CSF) TPA concentrations, the rate at which TPA clears, and the relationship between TPA concentration and biological activity. Methods Twelve patients with aneurysmal SAH and IVH, treated with endovascular coiling and ventricular drainage, were randomized to receive either 2 mg intraventricular TPA or placebo every 12 h (five doses). CT scans were performed 12, 48, and 72 h after initial administration, and blood was quantified using the SAH Sum and IVH Scores. CSF TPA and fibrin degradation product (D-dimer) concentrations were measured at baseline and 1, 6, and 12 h after the first dose using ELISA assays. Results Median CSF TPA concentrations in seven TPA-treated patients were 525 (IQR 352–2129), 323 (233–413), and 47 (29–283) ng/ml, respectively, at 1, 6, and 12 h after drug administration. Peak concentrations varied markedly (401–8398 ng/ml). Two patients still had slightly elevated levels (283–285 ng/ml) when the second dose was due after 12 h. There was no significant correlation between the magnitude of CSF TPA elevation and the rate of blood clearance or degree of D-dimer elevation. D-dimer peaked at 6 h, had declined by 12 h, and correlated strongly with radiographic IVH clearance (r = 0.82, p = 0.02). Conclusions The pharmacokinetics of intraventricular TPA administration varies between individual patients. TPA dose does not need to exceed 2 mg. The optimal administration interval is every 8–12 h..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Neurocritical care - 23(2015), 3 vom: 05. März, Seite 386-393 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kramer, Andreas H. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
D-dimer |
|---|
| Anmerkungen: |
© Springer Science+Business Media New York 2015 |
|---|
| doi: |
10.1007/s12028-015-0126-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2050024924 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2050024924 | ||
| 003 | DE-627 | ||
| 005 | 20230517040037.0 | ||
| 007 | tu | ||
| 008 | 200819s2015 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s12028-015-0126-9 |2 doi | |
| 035 | |a (DE-627)OLC2050024924 | ||
| 035 | |a (DE-He213)s12028-015-0126-9-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Kramer, Andreas H. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacokinetics and Pharmacodynamics of Tissue Plasminogen Activator Administered Through an External Ventricular Drain |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer Science+Business Media New York 2015 | ||
| 520 | |a Background Intraventricular hemorrhage (IVH) frequently complicates spontaneous intracerebral or subarachnoid hemorrhage (SAH). Administration of intraventricular tissue plasminogen activator (TPA) accelerates blood clearance, but optimal dosing has not been clarified. Using a standardized TPA dose, we assessed peak cerebrospinal fluid (CSF) TPA concentrations, the rate at which TPA clears, and the relationship between TPA concentration and biological activity. Methods Twelve patients with aneurysmal SAH and IVH, treated with endovascular coiling and ventricular drainage, were randomized to receive either 2 mg intraventricular TPA or placebo every 12 h (five doses). CT scans were performed 12, 48, and 72 h after initial administration, and blood was quantified using the SAH Sum and IVH Scores. CSF TPA and fibrin degradation product (D-dimer) concentrations were measured at baseline and 1, 6, and 12 h after the first dose using ELISA assays. Results Median CSF TPA concentrations in seven TPA-treated patients were 525 (IQR 352–2129), 323 (233–413), and 47 (29–283) ng/ml, respectively, at 1, 6, and 12 h after drug administration. Peak concentrations varied markedly (401–8398 ng/ml). Two patients still had slightly elevated levels (283–285 ng/ml) when the second dose was due after 12 h. There was no significant correlation between the magnitude of CSF TPA elevation and the rate of blood clearance or degree of D-dimer elevation. D-dimer peaked at 6 h, had declined by 12 h, and correlated strongly with radiographic IVH clearance (r = 0.82, p = 0.02). Conclusions The pharmacokinetics of intraventricular TPA administration varies between individual patients. TPA dose does not need to exceed 2 mg. The optimal administration interval is every 8–12 h. | ||
| 650 | 4 | |a Intraventricular hemorrhage | |
| 650 | 4 | |a Subarachnoid hemorrhage | |
| 650 | 4 | |a Tissue plasminogen activator | |
| 650 | 4 | |a Fibrinolysis | |
| 650 | 4 | |a Pharmacokinetics | |
| 650 | 4 | |a D-dimer | |
| 700 | 1 | |a Jenne, Craig |4 aut | |
| 700 | 1 | |a Holodinsky, Jessalyn K. |4 aut | |
| 700 | 1 | |a Todd, Stephanie |4 aut | |
| 700 | 1 | |a Roberts, Derek J. |4 aut | |
| 700 | 1 | |a Kubes, Paul |4 aut | |
| 700 | 1 | |a Zygun, David A. |4 aut | |
| 700 | 1 | |a Hill, Michael D. |4 aut | |
| 700 | 1 | |a Leger, Caroline |4 aut | |
| 700 | 1 | |a Wong, John H. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurocritical care |d Springer US, 2004 |g 23(2015), 3 vom: 05. März, Seite 386-393 |w (DE-627)539546593 |w (DE-600)2381896-7 |w (DE-576)9539546591 |x 1541-6933 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2015 |g number:3 |g day:05 |g month:03 |g pages:386-393 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s12028-015-0126-9 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_4219 | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2015 |e 3 |b 05 |c 03 |h 386-393 | ||